Rare human diseases represent a highly diverse collection of medical conditions affecting different organ systems and biological pathways.

Although each individual rare disease may affect a small number of patients, the combined burden of rare diseases is considerable.

A large proportion of rare diseases have a genetic origin.

They may result from pathogenic variants in single genes, chromosomal abnormalities, mitochondrial DNA alterations, repeat expansions, structural genomic changes, or more complex genetic mechanisms.

Diagnosis can be particularly challenging because many rare diseases present with non-specific symptoms.

Patients may visit multiple healthcare specialists before the underlying condition is recognized.

Traditional genetic testing often follows a sequential strategy in which individual genes are analyzed based on the suspected clinical diagnosis.

This approach can be inefficient when several genes can produce similar phenotypes.

The development of high-throughput genomic technologies has changed this diagnostic model.

Modern sequencing approaches allow hundreds or thousands of genes to be evaluated simultaneously.

Whole-exome sequencing and whole-genome sequencing can further expand the investigation to a much broader portion of the genome.

Genomic testing can therefore provide a molecular diagnosis even when the clinical phenotype is atypical or does not correspond precisely to a known disorder.

Genomic Basis of Rare Diseases

Rare diseases can arise from different types of genomic alterations.

Single-nucleotide variants may alter a single DNA base and can disrupt protein structure or gene regulation.

Small insertions and deletions can cause frameshifts or modify protein sequences.

Copy-number variants can result in deletion or duplication of genomic segments.

Structural variants may involve inversions, translocations, large deletions, or complex rearrangements.

Repeat expansions represent another important category of pathogenic variation.

Some disorders are caused by mitochondrial DNA variants or abnormalities involving mitochondrial genomes.

The wide range of possible variant types means that no single genomic technology can detect every disease-causing alteration with equal efficiency.

Major Genomic Approaches

Targeted Gene Sequencing

Targeted gene panels analyze a selected group of genes associated with a particular clinical condition.

For example, a panel may investigate genes associated with inherited cardiomyopathy, epilepsy, hereditary neuropathy, or metabolic disorders.

The focused design allows high sequencing depth and reduces the amount of irrelevant data.

Targeted panels can therefore be useful when clinical findings strongly suggest a particular disease category.

However, their major limitation is that a disease-causing gene cannot be identified if it is not included in the panel.

As new disease-associated genes continue to be discovered, panels may require regular updating.

Whole-Exome Sequencing

Whole-exome sequencing analyzes protein-coding regions of the genome.

Exons constitute a relatively small fraction of the human genome but contain many known disease-associated variants.

WES can therefore provide substantial diagnostic value in rare genetic disorders.

It is particularly useful for patients with unexplained developmental delay, intellectual disability, congenital anomalies, neurological disorders, and suspected metabolic diseases.

Trio-based WES, in which the patient and both biological parents are analyzed, can be especially informative.

Identification of de novo variants and analysis of inheritance patterns can help prioritize potentially disease-causing variants.

However, WES may have limited sensitivity for certain structural variants, repeat expansions, deep intronic variants, and poorly captured genomic regions.

Whole-Genome Sequencing

Whole-genome sequencing examines a much larger portion of the genome than WES.

It provides access to coding regions as well as many non-coding regions.

This broader coverage creates opportunities to identify variants that may be missed by targeted sequencing or exome analysis.

WGS can identify single-nucleotide variants and small insertions or deletions and may also detect copy-number and structural changes depending on sequencing technology and bioinformatic pipelines.

The large quantity of genomic data generated by WGS creates additional challenges for interpretation and storage.

Nevertheless, WGS is increasingly considered an important diagnostic strategy for patients with unexplained rare diseases.

Chromosomal and Copy-Number Analysis

Not all rare diseases are caused by small sequence variants.

Large deletions and duplications can disrupt genes or alter gene dosage.

Chromosomal microarray analysis has traditionally been an important tool for identifying copy-number abnormalities, particularly in patients with developmental delay, intellectual disability, congenital anomalies, and autism-spectrum phenotypes.

Modern sequencing technologies can also identify many copy-number changes.

Combining sequence-level and copy-number analysis can therefore improve diagnostic coverage.

Structural Variants and Long-Read Sequencing

Structural variants can involve large genomic regions and may be difficult to characterize using conventional short-read sequencing.

Long-read sequencing produces substantially longer DNA sequence reads.

This can improve characterization of repetitive regions, complex rearrangements, large insertions and deletions, and other difficult genomic structures.

Long-read approaches are particularly promising for rare diseases that remain undiagnosed after conventional sequencing.

They may also improve detection of repeat expansions associated with specific neurological and neuromuscular disorders.

Mitochondrial Genomic Analysis

Mitochondrial diseases can result from variants in either nuclear genes or mitochondrial DNA.

Mitochondrial genomic analysis can therefore play an important role when patients present with multisystem disease, neuromuscular abnormalities, metabolic disturbances, or unexplained energy-production defects.

Interpretation of mitochondrial variants requires consideration of heteroplasmy, tissue distribution, and clinical phenotype.

In some cases, testing of additional tissues may be necessary because the level of a mitochondrial variant can vary among tissues.

Genomic Diagnosis of Developmental Disorders

Developmental delay and intellectual disability are among the common clinical indications for genomic testing.

The underlying causes can involve chromosomal abnormalities, copy-number changes, single-gene disorders, and de novo variants.

Genomic sequencing can identify pathogenic variants even when clinical features are not sufficient to establish a specific syndrome.

A molecular diagnosis can provide information about prognosis, recurrence risk, and appropriate medical surveillance.

It can also assist families in making informed reproductive decisions.

Genomic Approaches in Neurological Rare Diseases

Many neurological rare diseases have substantial genetic heterogeneity.

Inherited epilepsy, hereditary neuropathies, ataxias, neuromuscular diseases, and neurodegenerative disorders can be caused by variants in numerous genes.

Genomic sequencing allows multiple potential causes to be investigated simultaneously.

However, some neurological diseases involve repeat expansions or other complex variants that may require specialized testing.

Therefore, a negative exome result does not necessarily exclude a genetic neurological disorder.

Genomic Diagnosis of Inherited Metabolic Disorders

Inherited metabolic disorders often present during infancy or childhood but can also appear in adulthood.

Biochemical testing can provide evidence of metabolic dysfunction, but molecular testing is often necessary to establish the underlying cause.

Genomic sequencing can identify pathogenic variants affecting metabolic enzymes, transport proteins, receptors, and regulatory pathways.

The combination of biochemical and genomic information can improve diagnostic accuracy.

Genomic Approaches in Hereditary Cancer

Although many cancers are sporadic, some patients carry inherited pathogenic variants that increase cancer susceptibility.

Genomic testing can identify variants associated with hereditary cancer syndromes.

A molecular diagnosis can influence cancer surveillance and may allow relatives to undergo targeted testing.

In some cases, germline genomic information can also contribute to treatment decisions.

Genetic counseling is important because results may have implications for multiple family members.

Review Design

The present article was developed as a narrative review of genomic approaches used in the diagnosis of rare human diseases.

Literature Search

Relevant peer-reviewed literature was considered from major biomedical and genomic research databases.

Search terms included combinations of “rare diseases,” “genomic diagnosis,” “whole-exome sequencing,” “whole-genome sequencing,” “targeted sequencing,” “structural variants,” “copy-number variants,” “long-read sequencing,” and “genetic diagnosis.”

Selection Criteria

Literature addressing genomic technologies, rare-disease diagnosis, variant detection, molecular interpretation, diagnostic yield, and clinical implementation was considered relevant.

Data Synthesis

The literature was organized according to major genomic technologies, variant classes, clinical applications, diagnostic benefits, limitations, and future developments.

Results

The reviewed evidence demonstrates that genomic technologies have substantially improved the diagnostic investigation of rare diseases.

Targeted gene panels provide efficient analysis for clinically defined disease categories.

Whole-exome sequencing provides broad analysis of protein-coding genes and is particularly useful for genetically heterogeneous disorders.

Whole-genome sequencing extends analysis beyond coding regions and can improve detection of diverse genomic alterations.

Chromosomal microarray remains useful for copy-number abnormalities, while long-read sequencing provides additional capabilities for complex structural variants and repetitive regions.

The integration of genomic results with detailed clinical information and family studies improves variant interpretation.

The diagnosis of rare human diseases has historically been difficult because of substantial clinical and genetic heterogeneity.

Patients may present with combinations of symptoms that do not correspond to established disease categories.

In such cases, traditional gene-by-gene testing may require extensive time and resources.

Genomic sequencing has changed this process by allowing simultaneous analysis of large numbers of genes.

Whole-exome sequencing has been particularly important in identifying disease-causing variants in patients with unexplained phenotypes.

The use of trio sequencing can further improve interpretation by determining whether a variant is inherited or has arisen de novo.

Whole-genome sequencing offers additional advantages because it examines genomic regions that are not routinely assessed by exome sequencing.

This broader approach may be particularly useful when a patient remains undiagnosed following conventional testing.

However, broader sequencing also creates a greater interpretation challenge.

Thousands of genetic variants may be detected in every individual, and most are not disease-causing.

Determining which variants are clinically relevant requires population-frequency data, functional evidence, inheritance information, phenotype matching, and clinical expertise.

Variants of uncertain significance remain a major challenge.

A VUS should not automatically be considered the cause of a patient's condition.

Further evidence may be required to establish or exclude pathogenicity.

Another important limitation is that certain genomic alterations remain difficult to detect using conventional short-read sequencing.

Repeat expansions, complex structural variants, highly repetitive regions, and some regulatory variants may require specialized technologies.

Long-read sequencing offers promising solutions to several of these limitations.

The integration of genomic data with other biological information is another important development.

Transcriptomic analysis can determine whether a genetic variant affects gene expression or RNA splicing.

Proteomic and metabolomic approaches can provide additional functional evidence.

Such multi-omics approaches may help resolve cases that remain unsolved after standard sequencing.

Advantages of Genomic Approaches

Limitations and Challenges

Despite major advances, genomic diagnosis is not without limitations.

A negative sequencing result does not necessarily exclude a genetic cause.

Some pathogenic variants may be located in regions that are poorly covered or difficult to interpret.

Structural variants and repeat expansions can remain undetected by conventional approaches.

Variant interpretation can also be complicated by incomplete penetrance and variable expressivity.

Another concern is the identification of incidental findings.

Sequencing may reveal medically relevant variants unrelated to the original reason for testing.

Patients should therefore receive appropriate information regarding the scope and possible outcomes of genomic testing.

Data privacy is also essential because genomic information is highly personal and can have implications for biological relatives.

Reanalysis of Genomic Data

One of the important advantages of genomic testing is that data can be reanalyzed.

A patient whose genome was initially classified as negative may receive a diagnosis several years later when new disease genes are discovered or previously uncertain variants are better understood.

Regular reanalysis can therefore improve the long-term diagnostic value of sequencing.

This approach is particularly important in rare diseases because knowledge of disease-associated genes continues to expand.

Clinical and Ethical Considerations

Genomic testing should be integrated with clinical evaluation rather than interpreted independently.

Detailed phenotyping can substantially improve variant prioritization.

Family history and segregation analysis can provide additional evidence.

Genetic counseling is important before and after testing.

Patients should understand the possible outcomes, including pathogenic findings, negative results, and uncertain variants.

The handling of incidental findings should follow appropriate clinical and ethical guidelines.

Confidentiality and secure genomic-data management are also essential.

Future Perspectives

The future of rare-disease diagnosis is likely to involve increasingly comprehensive genomic analysis.

Long-read sequencing may improve detection of complex structural variants and repeat expansions.

RNA sequencing may provide functional evidence for variants affecting transcription or splicing.

Artificial intelligence may assist in phenotype matching and variant prioritization.

Multi-omics integration could connect genomic alterations with changes in RNA, proteins, and metabolic pathways.

International data-sharing initiatives may also improve recognition of extremely rare variants by allowing clinicians and researchers to compare cases across populations.

As genomic technologies become more accessible, earlier molecular diagnosis may become increasingly achievable.

Genomic approaches have fundamentally changed the diagnosis of rare human diseases.

Targeted sequencing, whole-exome sequencing, whole-genome sequencing, chromosomal analysis, mitochondrial sequencing, and long-read technologies provide complementary methods for identifying disease-causing genomic alterations.

Their greatest value lies in patients with genetically heterogeneous, clinically atypical, or previously unexplained disorders.

However, accurate diagnosis requires more than sequencing alone.

Clinical phenotyping, family studies, variant interpretation, functional investigation, and appropriate genetic counseling are essential components of genomic medicine.

Future integration of long-read sequencing, transcriptomics, artificial intelligence, and multi-omics approaches is expected to improve diagnostic accuracy further.

The continued development of genomic medicine offers the potential to shorten diagnostic journeys, improve patient management, support families, and advance understanding of rare human diseases.

1. Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nature Reviews Genetics. 2013;14:681–691.
2. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. New England Journal of Medicine. 2014;370:2418–2425.
3. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. New England Journal of Medicine. 2013;369:1502–1511.
4. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–1879.
5. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nature Reviews Genetics. 2018;19:253–268.
6. Posey JE. Genome sequencing and implications for rare disorders. Nature Reviews Genetics. 2019;20:81–94.
7. Genovese G, Fromer M, Stahl EA, et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nature Neuroscience. 2016;19:1433–1441.
8. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
9. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics. 2016;17:333–351.
10. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-genome sequencing across clinical indications. Genetics in Medicine. 2016;18:696–704.
11. Manolio TA, Rowley R, Williams MS, et al. Opportunities, resources, and techniques for implementing genomics in clinical care. Nature Genetics. 2018;50:1112–1121.
12. Stark Z, Tan TY, Chong B, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genetics in Medicine. 2016;18:1090–1096.
13. Miller DT, Lee K, Abul-Husn NS, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing. Genetics in Medicine. 2023;25:1003–1011.
14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants. Genetics in Medicine. 2015;17:405–424.
15. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469–476.
16. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends in Genetics. 2014;30:418–426.
17. Levy-Sakin M, Ebenstein Y. Beyond sequencing: next-generation technologies for the future of genomic research. Genome Biology. 2013;14:201.
18. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. American Journal of Human Genetics. 2010;86:749–764.
19. Ashley EA. Towards precision medicine. Nature Reviews Genetics. 2016;17:507–522.
20. Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with new genomic technologies. New England Journal of Medicine. 2018;379:1157–1168.